Blood levels of reduced halopertool versus clinical efficacy and extrapyramidal side effects of haloperidol-Reference-Cited by-同舟云学术

Blood levels of reduced halopertool versus clinical efficacy and extrapyramidal side effects of haloperidol

Published:1997-02 Issue:2 Volume:21 Page:299-311
ISSN:0278-5846
Container-title:Progress in Neuro-Psychopharmacology and Biological Psychiatry
language:en
Short-container-title:Progress in Neuro-Psychopharmacology and Biological Psychiatry

Author:

Lane Hsien-Yuan,Lin Hsin-Nan,Hu Oliver Yoa-Pu,Chen Chiao-Chicy,Jann Michael I.,Chang Wen-Ho

Publisher

Elsevier BV

Subject

Biological Psychiatry,Pharmacology

Reference32 articles.

1. A uultidinensional (phanacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia with particular reference to drug resistance;Altaiura;Schizophr. Res.,1993

2. Significance of neuroleptic dose and plasma level in the pharmacological treat- Dent of psychoses;Baldessarini;Arch. Gen. Psychiatry,1988

3. Metabolites of haloperidol display preferential activity at signa receptors compared to dopanine D2 receptor;Bowen;Eur.J. Phanacol.,1990

4. Haloperidol and reduced haloperidol induced exacerbation of the dystonia produced by kappa opioid U50, 488H in guinea pigs correlate with inhibition of signa binding sites;Brent;Neuropsychopharmacology,1994

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Relation between the Plasma Concentrations of Long-Acting Atypical Antipsychotics and Clinical Effectiveness in Patients Affected by Schizophrenia or Schizoaffective Disorder: A Comprehensive Overview;Current Pharmaceutical Design;2021-10-26

2. The Associations between Central Nervous System Diseases and Haemostatic Disorders;CNS & Neurological Disorders - Drug Targets;2019-07-17

3. Classics in Chemical Neuroscience: Haloperidol;ACS Chemical Neuroscience;2017-02-15

4. Antipsychotics;Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents;2016

5. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers;Pharmacogenomics;2013-10